Cargando…
Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
Anemia, complicating the course of chronic kidney disease, is a significant parameter, whether interpreted as subjective impairment or an objective prognostic marker. Renal anemia is predominantly due to relative erythropoietin (EPO) deficiency. EPO inhibits apoptosis of erythrocyte precursors. Stud...
Autores principales: | Biggar, Patrick, Kim, Gheun-Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Nephrology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592888/ https://www.ncbi.nlm.nih.gov/pubmed/28904872 http://dx.doi.org/10.23876/j.krcp.2017.36.3.209 |
Ejemplares similares
-
Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019) -
A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022) -
Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023) -
Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
por: Kim, Sun Moon, et al.
Publicado: (2016) -
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)